Back to All Combinations

PTEN Loss

Intermediate Prognosis
10.00% Prevalence Level 3 PIK3CA Pathway
Genes Involved
PTEN
Treatment Implications

Activates PI3K pathway. Mixed data on anti-EGFR resistance.

Recommended Treatments
Standard therapy
Consider aspirin
Treatments to Avoid

No specific contraindications noted

Study References

Multiple studies

Key Statistics
10.00%
Prevalence in CRC
No
Targetable
Clinical Notes
May inform aspirin use.
Information

Category: PIK3CA Pathway

Evidence Level: Level 3

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.